EcoDrugPlus


Keyword(s):	Human Metabolites
Molecule Category	Free-form
UNII	2F97U2I94O
EPA CompTox	DTXSID10865703

Keyword(s):

Human Metabolites

Molecule Category

Free-form

UNII

2F97U2I94O

EPA CompTox

DTXSID10865703


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	HEKJOMVJRYMUDB-UHFFFAOYSA-N
Smiles	CC(C)C1CCC2CC(=O)CCC2C1
InChI	InChI=1S/C13H22O/c1-9(2)10-3-4-12-8-13(14)6-5-11(12)7-10/h9-12H,3-8H2,1-2H3

InChI Key

HEKJOMVJRYMUDB-UHFFFAOYSA-N

Smiles

CC(C)C1CCC2CC(=O)CCC2C1

InChI

InChI=1S/C13H22O/c1-9(2)10-3-4-12-8-13(14)6-5-11(12)7-10/h9-12H,3-8H2,1-2H3

Property Name	Value
Molecular Formula	C13H22O1
Molecular Weight	194.17
AlogP	3.43
Hydrogen Bond Acceptor	1.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	1.0
Polar Surface Area	17.07
Molecular species	None
Aromatic Rings	0.0
Heavy Atoms	14.0

Property Name

Value

Molecular Formula

C13H22O1

Molecular Weight

194.17

AlogP

3.43

Hydrogen Bond Acceptor

1.0

Hydrogen Bond Donor

0.0

Number of Rotational Bond

1.0

Polar Surface Area

17.07

Molecular species

None

Aromatic Rings

0.0

Heavy Atoms

14.0

Resources	Reference
CAS NUMBER	34131-98-1
NORMAN SUSDAT
FDA SRS	2F97U2I94O
PubChem	118134
ChemSpider	105571.0

Resources

Reference

CAS NUMBER

34131-98-1

NORMAN SUSDAT

FDA SRS

2F97U2I94O

PubChem

118134

ChemSpider

105571.0


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

2(1H)-NAPHTHALENONE, OCTAHYDRO-6-(1-METHYLETHYL)-

Structure

Physicochemical Descriptors

Cross References